Washington Post coverage of Geron halting its stem cell trial on spinal cord injury

Lots in the papers this morning about the US company, Geron, halting its stem cell study on spinal cord injury.

I thought I would share this coverage from the Washington Post.

Geron’s decision highlights a lot of interesting issues around science funding..

..the long-term nature of science
…the difficulties for the private sector in keeping shareholders on side for such a long-term venture
…..the importance therefore of public funding in sustaining this sort of work
……and, as the Post says, the ‘fledgling’ nature of the stem cell ‘market’ if I can put it like that.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s